Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M167,357Revenue $M11,202Net Margin (%)42.8Z-Score9.0
Enterprise Value $M168,401EPS $1.8Operating Margin %56.2F-Score8
P/E(ttm))24.6Cash Flow Per Share $4.3Pre-tax Margin (%)54.2Higher ROA y-yY
Price/Book10.510-y EBITDA Growth Rate %0Quick Ratio2.2Cash flow > EarningsN
Price/Sales10.65-y EBITDA Growth Rate %8.2Current Ratio2.5Lower Leverage y-yY
Price/Cash Flow17.4y-y EBITDA Growth Rate %122ROA % (ttm)29.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)59.4Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,512ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 107.1838%New holding, 1710000 sh.1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 107.1838%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 107.1838%New holding, 466853 sh.466,853
GILDJohn Rogers 2014-06-30 Add0.25%$65.48 - $83.02
($77.76)
$ 107.1838%Add 60.78%638,734
GILDKen Fisher 2014-06-30 Add0.07%$65.48 - $83.02
($77.76)
$ 107.1838%Add 62.11%975,483
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 107.1838%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 107.1838%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 107.1838%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 107.1838%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 107.1838%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 107.1837%Add 7.91%345,320
GILDRay Dalio 2014-03-31 Add0.12%$68.55 - $83.95
($78.44)
$ 107.1837%Add 541.42%247,721
GILDJohn Rogers 2014-03-31 Add0.06%$68.55 - $83.95
($78.44)
$ 107.1837%Add 22.5%397,273
GILDGeorge Soros 2014-03-31 Buy 0.04%$68.55 - $83.95
($78.44)
$ 107.1837%New holding, 50000 sh.50,000
GILDJohn Burbank 2014-03-31 Buy 0.01%$68.55 - $83.95
($78.44)
$ 107.1837%New holding, 3619 sh.3,619
GILDMario Gabelli 2014-03-31 Add$68.55 - $83.95
($78.44)
$ 107.1837%Add 31.65%44,240
GILDDaniel Loeb 2014-03-31 Sold Out -1.9%$68.55 - $83.95
($78.44)
$ 107.1837%Sold Out0
GILDJohn Griffin 2014-03-31 Sold Out -0.48%$68.55 - $83.95
($78.44)
$ 107.1837%Sold Out0
GILDVanguard Health Care Fund 2014-03-31 Reduce-0.46%$68.55 - $83.95
($78.28)
$ 107.1837%Reduce -41.41%2,713,300
GILDKen Fisher 2014-03-31 Reduce-0.07%$68.55 - $83.95
($78.28)
$ 107.1837%Reduce -40.46%601,758
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD Joel Greenblatt 2014-06-30466,8530.030.48New Buy
GILD Ken Heebner 2014-06-301,710,0000.113.8New Buy
GILD Ken Fisher 2014-06-30975,4830.060.17+62.11%
GILD John Rogers 2014-06-30638,7340.040.65+60.78%
GILD Ray Dalio 2014-06-30349,8210.020.22+41.22%
GILD Julian Robertson 2014-06-30443,9110.0313.4+28.55%
GILD Mario Gabelli 2014-06-3049,17000.02+11.14%
GILD John Burbank 2014-06-303,77400.01+4.28%
GILD Jean-Marie Eveillard 2014-06-3040000
GILD Ronald Muhlenkamp 2014-06-30144,7150.012.1-24.63%
GILD Mariko Gordon 2014-06-3011,65400.04-35.57%
GILD Vanguard Health Care Fund 2014-06-301,633,7000.110.36-39.79%
GILD George Soros 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cogan John FrancisDirector 2014-10-21Sell15,000$104.086.4view
MILLIGAN JOHN FPresident and COO 2014-10-07Sell146,895$104.65.87view
Carter Paul RutherfordEVP Commercial Ops 2014-10-01Sell2,000$106.394.09view
Alton Gregg HEVP, Corp & Med Affairs 2014-10-01Sell33,000$105.984.49view
MARTIN JOHN CChairman and CEO 2014-10-01Sell140,625$105.914.56view
Whitley Richard JamesDirector 2014-10-01Sell5,000$106.993.51view
Carter Paul RutherfordEVP Commercial Ops 2014-09-26Sell2,000$107.473.04view
Cogan John FrancisDirector 2014-09-22Sell5,000$106.63.88view
MILLIGAN JOHN FPresident and COO 2014-09-08Sell146,895$105.994.48view
Alton Gregg HEVP, Corp & Med Affairs 2014-09-02Sell33,000$108.581.99view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about gild:

Articles On GuruFocus.com
Gilead Sciences – From The Long Term Perspective Oct 08 2014 
There's More to Gilead Sciences than a Successful Drug Sep 26 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
Gilead Sciences: Up Over 1,100% And Still Cheap Sep 09 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Everything's Going Right for Gilead Sciences Aug 26 2014 
New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV Aug 18 2014 
Julian Robertson Buys Tableau Software, Facebook, Netflix, Sells Ulta Salon, EBay, EQT Aug 14 2014 
Creating Cures And Dividends Where None Existed Before With Gilead Sciences Jul 26 2014 
Analyzing Why Gilead Sciences is Still a Great Buy Jul 24 2014 

More From Other Websites
Gilead Sciences: Harvoni "Off to the Races" Oct 24 2014
High Drug Prices Could Increase Industry Innovation Oct 24 2014
Alexion Pharmaceuticals: Nice Earnings, Too Expensive? Oct 23 2014
Could High Drug Prices Be Bad For Innovation? Oct 23 2014
Biotechs Show Fed Chief's Not Much Of A Stock Analyst Oct 22 2014
Gilead's Hep C Dream Drug Faces Demanding Investors Oct 22 2014
Value in biotech: Pro Oct 22 2014
Biogen Leads 5 Top Biotech Stocks As Earnings Loom Oct 21 2014
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 Oct 21 2014
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 Oct 21 2014
How Gilead Sciences Became A Big Name In Biotech Oct 21 2014
Will High Price Hurt Gilead Sciences' New Hep-C Drug? Oct 20 2014
Senate Lawmaker Eyes Hearing on the Cost of Hepatitis C Treatments Oct 20 2014
Perrigo CEO Constructs "Five Pillars" For Success Oct 17 2014
Stocks Up Big Friday, Recover Early Week Losses Oct 17 2014
Gilead's Harvoni Receives Notice of Compliance from Canada Oct 17 2014
The top 10 best-performing CEOs Oct 17 2014
Health Canada issues notice of compliance for Gilead's Harvoni™ (ledipasvir/sofosbuvir), the first... Oct 16 2014
Health Canada issues notice of compliance for Gilead's Harvoni™ (ledipasvir/sofosbuvir), the first... Oct 16 2014
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the... Oct 16 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK